• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因组学、转录组学、表观遗传学和代谢组学生物标志物在 2 型糖尿病和心血管疾病个体化预防中的前景。

The Prospect of Genomic, Transcriptomic, Epigenetic and Metabolomic Biomarkers for The Personalized Prevention of Type 2 Diabetes and Cardiovascular Diseases.

机构信息

Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

出版信息

Curr Vasc Pharmacol. 2023;21(3):185-196. doi: 10.2174/1570161121666230510141338.

DOI:10.2174/1570161121666230510141338
PMID:37165508
Abstract

Cardiometabolic diseases, such as type 2 diabetes mellitus (DM) and cardiovascular disease (CVD), are a great health concern. The strategies aimed to increase awareness and prevention, in conjunction with timely diagnosis and optimal management of these conditions, represent the main lines of action to improve life expectancy and quality. In recent years, the introduction of innovative therapies for the treatment of DM and CVD has provided new hope for high-risk patients. Yet, the implementation of preventive measures in achieving cardiometabolic health is far from successful and requires further improvement. The development of cardiometabolic disorders is a complex, multifactorial process involving several metabolic pathways as well as genetic and environmental factors. Decreasing cumulative exposure during the entire life course and timely recognition and targeting of potential riskenhancing factors could pave the way toward more successful prevention of cardiometabolic disorders. Nowadays, in the era of "omics" technologies, it is possible to identify novel biomarkers and therapeutic targets, which offers the possibility to apply an individualized approach for each patient. This review will discuss potential applications of genomic, transcriptomic, epigenetic and metabolomic biomarkers for the personalized prevention of cardiometabolic diseases.

摘要

心血管代谢疾病,如 2 型糖尿病(DM)和心血管疾病(CVD),是一个严重的健康问题。旨在提高认识和预防的策略,结合这些疾病的及时诊断和最佳管理,是提高预期寿命和生活质量的主要行动方向。近年来,针对 DM 和 CVD 的治疗的创新疗法的引入为高危患者带来了新的希望。然而,在实现心血管代谢健康方面,预防措施的实施远未成功,需要进一步改进。心血管代谢紊乱的发展是一个复杂的、多因素的过程,涉及多个代谢途径以及遗传和环境因素。减少整个生命过程中的累积暴露,并及时识别和针对潜在的风险增强因素,可能为更成功地预防心血管代谢紊乱铺平道路。如今,在“组学”技术时代,可以识别新的生物标志物和治疗靶点,这为每位患者应用个体化方法提供了可能。这篇综述将讨论基因组、转录组、表观基因组和代谢组生物标志物在心血管代谢疾病个体化预防中的潜在应用。

相似文献

1
The Prospect of Genomic, Transcriptomic, Epigenetic and Metabolomic Biomarkers for The Personalized Prevention of Type 2 Diabetes and Cardiovascular Diseases.基因组学、转录组学、表观遗传学和代谢组学生物标志物在 2 型糖尿病和心血管疾病个体化预防中的前景。
Curr Vasc Pharmacol. 2023;21(3):185-196. doi: 10.2174/1570161121666230510141338.
2
Role of Epigenetics and Metabolomics in Predicting Endothelial Dysfunction in Type 2 Diabetes.表观遗传学和代谢组学在预测 2 型糖尿病内皮功能障碍中的作用。
Adv Biol (Weinh). 2023 Sep;7(9):e2300172. doi: 10.1002/adbi.202300172. Epub 2023 Aug 24.
3
Omics and Cardiometabolic Disease Risk Prediction.组学与心血管疾病风险预测。
Annu Rev Med. 2020 Jan 27;71:163-175. doi: 10.1146/annurev-med-042418-010924.
4
Predictive biomarkers for type 2 of diabetes mellitus: Bridging the gap between systems research and personalized medicine.2 型糖尿病的预测生物标志物:弥合系统研究与个性化医学之间的差距。
J Proteomics. 2018 Sep 30;188:59-62. doi: 10.1016/j.jprot.2018.03.004. Epub 2018 Mar 5.
5
Multiplex Biomarker Approaches in Type 2 Diabetes Mellitus Research.2型糖尿病研究中的多重生物标志物方法。
Methods Mol Biol. 2017;1546:37-55. doi: 10.1007/978-1-4939-6730-8_3.
6
Epigenetic epidemiology: the rebirth of soft inheritance.表观遗传学流行病学:软遗传的重生。
Ann Nutr Metab. 2011;58 Suppl 2:8-15. doi: 10.1159/000328033. Epub 2011 Aug 12.
7
Personalized Management of Cardiovascular Disorders.心血管疾病的个体化管理。
Med Princ Pract. 2017;26(5):399-414. doi: 10.1159/000481403. Epub 2017 Sep 11.
8
Biomarkers for the prediction of type 2 diabetes and cardiovascular disease.预测 2 型糖尿病和心血管疾病的生物标志物。
Clin Pharmacol Ther. 2011 Jul;90(1):52-66. doi: 10.1038/clpt.2011.93. Epub 2011 Jun 8.
9
Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus.心血管代谢风险评估:预防心血管疾病和糖尿病的一种方法。
Clin Cornerstone. 2005;7(2-3):7-16. doi: 10.1016/s1098-3597(05)80063-8.
10
Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients.糖尿病患者心血管风险预测中的差异表观遗传因素。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):239-247. doi: 10.1093/ehjcvp/pvz062.

引用本文的文献

1
Applications and challenges of biomarker-based predictive models in proactive health management.基于生物标志物的预测模型在主动健康管理中的应用与挑战
Front Public Health. 2025 Aug 18;13:1633487. doi: 10.3389/fpubh.2025.1633487. eCollection 2025.